We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+5%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$40.3B
AUM Growth
+$535M
(+1.3%)
Cap. Flow
-$468M
Cap. Flow
% of AUM
-1.16%
Top 10 Holdings %
Top 10 Hldgs %
15.78%
Holding
2,279
New
170
Increased
711
Reduced
1,071
Closed
189
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$178M |
| 2 |
LyondellBasell Industries
LYB
|
+$133M |
| 3 |
AT&T
T
|
+$124M |
| 4 |
Stanley Black & Decker
SWK
|
+$101M |
| 5 |
Pfizer
PFE
|
+$93.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Clorox
CLX
|
+$229M |
| 2 |
Gilead Sciences
GILD
|
+$164M |
| 3 |
Broadcom
AVGO
|
+$149M |
| 4 |
KeyCorp
KEY
|
+$145M |
| 5 |
Darden Restaurants
DRI
|
+$125M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.22% |
| 2 | Technology | 14.47% |
| 3 | Financials | 10.84% |
| 4 | Industrials | 9.01% |
| 5 | Consumer Discretionary | 8.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SPNS
601
DELISTED
Sapiens International
SPNS
| $7.67M | 0.02% |
288,226
-9,141
| -3% | -$216K |
|
|
EVBG
602
DELISTED
Everbridge, Inc. Common Stock
EVBG
| $7.61M | 0.02% |
282,774
-4,433
| -2% | -$120K |
|
603
Arthur J. Gallagher & Co
AJG
$63.6B
| $7.59M | 0.02% |
34,580
-6,120
| -15% | -$1.27M |
|
604
IPG Photonics
IPGP
$3.2B
| $7.51M | 0.02% |
55,280
-61,424
| -53% | -$7.24M |
|
605
Huron Consulting
HURN
$2.45B
| $7.5M | 0.02% |
88,301
-2,269
| -3% | -$186K |
|
606
Adaptive Biotechnologies
ADPT
$4.26B
| $7.46M | 0.02% |
1,112,487
-63,569
| -5% | -$473K |
|
607
BridgeBio Pharma
BBIO
$13.4B
| $7.46M | 0.02% |
433,921
+178,353
| +70% | +$2.68M |
|
608
Ovintiv
OVV
$18.5B
| $7.45M | 0.02% |
195,616
+130,639
| +201% | +$4.72M |
|
609
CME Group
CME
$98.9B
| $7.44M | 0.02% |
40,130
-1,369
| -3% | -$253K |
|
610
Dentsply Sirona
XRAY
$1.96B
| $7.39M | 0.02% |
184,580
-66,860
| -27% | -$2.66M |
|
611
Newmark Group
NMRK
$2.58B
| $7.3M | 0.02% |
1,172,971
-25,107
| -2% | -$155K |
|
612
SI-BONE Inc
SIBN
$831M
| $7.29M | 0.02% |
+270,206
| New | +$6.59M |
|
613
Mettler-Toledo International
MTD
$26.7B
| $7.27M | 0.02% |
5,540
+22
| +0.4% | +$30.9K |
|
614
Motorola Solutions
MSI
$77.6B
| $7.25M | 0.02% |
24,720
+2,094
| +9% | +$600K |
|
615
TELA Bio
TELA
$48.9M
| $7.25M | 0.02% |
+715,300
| New | +$7.32M |
|
616
Sociedad Química y Minera de Chile
SQM
$19.8B
| $7.13M | 0.02% |
98,143
| – | – |
|
|
CHS
617
DELISTED
Chicos FAS, Inc.
CHS
| $7.13M | 0.02% |
1,332,000
-445,878
| -25% | -$2.33M |
|
618
BorgWarner
BWA
$12.7B
| $7.07M | 0.02% |
164,291
+22,984
| +16% | +$945K |
|
619
Codexis
CDXS
$153M
| $7.07M | 0.02% |
2,525,065
+2,038,716
| +419% | +$6.59M |
|
|
NEXN
620
Nexxen International
NEXN
$527M
| $7.06M | 0.02% |
980,100
| – | – |
|
621
Target
TGT
$70.1B
| $7.06M | 0.02% |
53,491
+3,150
| +6% | +$467K |
|
622
Vontier
VNT
$4.34B
| $7.04M | 0.02% |
218,600
+124,826
| +133% | +$3.6M |
|
623
Hims & Hers Health
HIMS
$6.5B
| $7M | 0.02% |
744,900
-42,519
| -5% | -$422K |
|
624
Establishment Labs
ESTA
$2.13B
| $6.96M | 0.02% |
+101,500
| New | +$7.01M |
|
625
PPG Industries
PPG
$23.3B
| $6.94M | 0.02% |
46,815
+22,447
| +92% | +$3.13M |
|
Similar funds
Federated Hermes's Q2 2023 Portfolio in Review
As of Q2 2023, Federated Hermes held 2,279 positions worth $40.3B, up 1.3% from $39.7B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Federated Hermes's Q2 2023 filing shows 170 new, 711 increased, 1,071 reduced and 189 closed positions. Its largest new stake was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M. The largest sale was Clorox, an estimated $229M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 20% a quarter earlier, followed by Technology and Financials.
- Federated Hermes's largest Q2 2023 buy was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M.
- Federated Hermes added most to Amgen in Q2 2023, an estimated $178M increase.
- Federated Hermes's biggest Q2 2023 reduction was Clorox, cutting an estimated $229M.
- Federated Hermes fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $55.4M.
- Federated Hermes's ten largest holdings make up 16% of its $40.3B portfolio in Q2 2023.
- Federated Hermes opened 170 new positions and closed 189 in Q2 2023.
- Federated Hermes's portfolio value rose 1.3% quarter-over-quarter to $40.3B.
Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.